Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

The Cooper Companies, Inc. (COO) — XLV Health Care · S&P 500 Profile |The Cooper Companies公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

The Cooper Companies, Inc. (COO) — Business, History & S&P 500 Profile | The Cooper Companies公司介紹

The Cooper Companies, Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #473 · The Cooper Companies公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 5, 2026
Financials: FY2025
MARKET CAP
$12.31B
Nov 5, 2026
S&P 500 WEIGHT
0.02%
Rank #473 · Nov 5, 2026
SECTOR RANK
#54
Health Care · Nov 5, 2026
S&P 500 RANK
#473
0.02% · Nov 5, 2026

SNAPSHOT

TickerCOO
CompanyThe Cooper Companies, Inc.
GICS sector / industryHealth Care (XLV) / Health Care Supplies
S&P 500 rank (by weight)#473 · 0.02% (Nov 5, 2026)
Sector rank#54 of 60 in Health Care (Nov 5, 2026)
HeadquartersSan Ramon, California, U.S.
Founded1958
CEOWalter M. Rosebrough Jr. (Interim Executive Chair, overseeing day-to-day operations; permanent CEO search underway)
EmployeesMore than 15,000 (as of October 31, 2025)
Market cap$12.31B (Nov 5, 2026)
SEC filingsEDGAR — CIK 711404

WHAT IT DOES

The Cooper Companies, Inc., branded CooperCompanies, is a San Ramon, California-based global medical device company with two businesses. CooperVision develops, manufactures and markets soft contact lenses — daily disposables, two-week and monthly lenses for myopia, astigmatism and presbyopia, plus the MiSight 1 day lens, the first product approved by the U.S. FDA to slow the progression of myopia in children aged 8–12 at the start of treatment. CooperSurgical serves fertility and women's health: products and services for fertility clinics (IVF devices, genetic testing, donor egg and sperm banking, cryostorage) and medical devices used in offices, surgery centres and hospitals, including contraception and labour and delivery products. Fiscal 2025 revenue was $4.09B, split $2.74B CooperVision and $1.35B CooperSurgical, with manufacturing concentrated in the Americas, Europe and Costa Rica.

BUSINESS SEGMENTS

CooperVisionOne of the world's largest soft contact lens makers: single-use, two-week and monthly lenses in silicone hydrogel and other materials, including toric lenses for astigmatism, multifocal lenses for presbyopia, the MiSight 1 day myopia-management lens for children, and ortho-k and scleral specialty lenses, sold to wearers via eye care practitioners. FY2025 net sales $2,743.8M.
CooperSurgicalFertility and women's health products and services: more than 600 offerings including IVF and fertility clinic products and genomic services, egg and sperm donation and cryostorage (including cord blood and tissue storage), contraception, and medical devices for offices, surgery centres and hospitals. FY2025 net sales $1,348.6M (office and surgical $824.0M; fertility $524.6M).
Two operating segments per the fiscal 2025 Form 10-K (Note 12); corporate selling, general and administrative costs ($90.1M in FY2025) are not allocated to the segments, so segment operating income (CooperVision $729.6M; CooperSurgical $43.4M) does not sum to consolidated operating income.

HISTORY

YearMilestone
1958Parker Montgomery buys Martin H. Smith Co., the origin of today's company; it becomes Cooper, Tinsley Laboratories in 1961 and Cooper Laboratories in 1967.
1972Cooper enters the contact lens business by acquiring British lens maker GlobalVision.
1987The company is renamed The Cooper Companies and is later restructured around CooperVision and CooperSurgical (the latter formed as a business unit in 1990).
2014CooperVision acquires UK contact lens maker Sauflon Pharmaceuticals for about $1.2B, adding Clariti lenses and daily-disposable capacity.
2021CooperSurgical acquires Generate Life Sciences for $1.6B in December 2021, building a leading fertility services platform; an $875M acquisition of Cook Medical's reproductive health business was announced in February 2022 but was terminated in August 2023 after FTC scrutiny and never closed.

COMPETITIVE POSITION

  • Johnson & Johnson Vision (Acuvue) — the largest global contact lens rival.
  • Alcon — a top-two contact lens maker and CooperVision's closest scale competitor.
  • Bausch + Lomb — competes in contact lenses and eye health products.
  • In fertility and women's health: Vitrolife, Cook Medical (remaining lines) and other specialist device makers.

FINANCIAL SNAPSHOT

Total revenue$4.09B (FY2025 revenue)
Operating income$682.9M (FY2025 operating income)
Net income$374.9M (FY2025 net income)
Diluted EPS$1.87 (FY2025 diluted EPS)
Source: The Cooper Companies, Inc. fiscal 2025 Form 10-K (period ended October 31, 2025; filed December 5, 2025). Exact figures: total revenue $4,092.4M; operating income $682.9M; net income $374.9M; diluted EPS $1.87. The company reported a workforce of more than 15,000 as of October 31, 2025 (52% in the Americas, 42% in EMEA, 6% in Asia Pacific). Fiscal 2026 results were not yet filed in a Form 10-K as of November 5, 2026.

KEY RISKS

  • Leadership transition: President and CEO Albert G. White III stepped down on October 27, 2026, with an interim Executive Chair in place and a permanent CEO search underway.
  • Contact lens competition and pricing pressure from Alcon, Johnson & Johnson Vision and Bausch + Lomb, plus private-label and direct-to-consumer brands.
  • CooperSurgical margin and integration risk after debt-funded fertility acquisitions (Generate Life Sciences).
  • Regulatory and product-quality risk across FDA and international approvals for lenses and medical devices, and currency exposure from a global sales and manufacturing footprint.

WHY IT MATTERS FOR THE S&P 500

Cooper Companies is a small-weight Health Care constituent: rank #473 by weight at 0.02% as of Nov 5, 2026, and #54 of 60 in Health Care. It is the index's purest large-scale exposure to the global contact lens market, paired with a fertility and women's health device business built through acquisitions.

SOURCES & METHODOLOGY

Financials, segments, headquartersThe Cooper Companies, Inc. fiscal 2025 Form 10-K via SEC EDGAR (see Financial Snapshot note); headquarters, CEO and history via the Form 10-K and Wikipedia company profile
Index weight & ranksSlickcharts S&P 500 weights, fetched Nov 5, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS)
Market cap$12.31B (Slickcharts, Nov 5, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

COO

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號COO
公司The Cooper Companies, Inc.(The Cooper Companies)
GICS 板塊/行業健康護理(XLV)/醫療用品
標普500排名(按權重)#473 · 0.02%(Nov 5, 2026)
板塊內排名健康護理板塊 #54(共 60 家)(Nov 5, 2026)
總部美國加利福尼亞州聖拉蒙
成立1958年
執行長Walter M. Rosebrough Jr.(臨時執行主席,主持日常營運;常任行政總裁遴選進行中)
員工逾15,000人(截至2025年10月31日)
市值$12.31B(Nov 5, 2026)
SEC 申報EDGAR — CIK 711404

業務概覽

The Cooper Companies, Inc.(品牌名稱 CooperCompanies)是一家總部位於加利福尼亞州聖拉蒙的全球醫療器械公司,旗下有兩項業務。CooperVision 開發、製造及銷售軟性隱形眼鏡 — 包括日拋、兩星期及月拋鏡片,矯正近視、散光及老花,另有 MiSight 1 day 鏡片,是首款獲美國食品藥物管理局批准、用於減緩8至12歲開始治療兒童近視加深的產品。 CooperSurgical 服務生育及女性健康市場:為生育診所提供產品及服務(體外受精器械、基因檢測、捐贈卵子及精子儲存、冷凍保存),以及供診所、手術中心及醫院使用的醫療器械,包括避孕及分娩產品。2025財年收入40.92億美元,其中 CooperVision 佔27.44億美元、CooperSurgical 佔13.49億美元,生產主要集中於美洲、歐洲及哥斯達黎加。

業務板塊

CooperVision(視力護理)全球最大軟性隱形眼鏡製造商之一:以矽水凝膠及其他物料製造即棄、兩星期及月拋鏡片,包括矯正散光的散光鏡片、矯正老花的漸進鏡片、兒童近視管理鏡片 MiSight 1 day,以及角膜塑形及鞏膜等特殊鏡片,經眼科護理專業人員售予佩戴者。2025財年淨銷售額27.44億美元(2,743.8百萬美元)。
CooperSurgical(外科及生育)生育及女性健康產品和服務:逾600項產品及服務,包括體外受精及生育診所產品和基因服務、卵子及精子捐贈和冷凍保存(包括臍帶血及臍帶組織儲存)、避孕產品,以及供診所、手術中心及醫院使用的醫療器械。2025財年淨銷售額13.49億美元(1,348.6百萬美元)(診所及外科8.24億美元;生育5.25億美元)。
根據2025財年 Form 10-K(附註12),公司設有兩個營運分部;企業銷售、一般及行政開支(2025財年9,010萬美元)並不分攤至各分部,故分部經營溢利(CooperVision 7.30億美元;CooperSurgical 0.43億美元)合計不等於綜合經營溢利。

歷史

年份里程碑
1958Parker Montgomery 購入 Martin H. Smith Co.,成為今日公司的起源;公司於1961年改稱 Cooper, Tinsley Laboratories,1967年再改稱 Cooper Laboratories。
1972Cooper 收購英國鏡片製造商 GlobalVision,進軍隱形眼鏡業務。
1987公司更名為 The Cooper Companies,其後圍繞 CooperVision 及 CooperSurgical 重組(後者於1990年成為業務部門)。
2014CooperVision 以約12億美元收購英國隱形眼鏡製造商 Sauflon Pharmaceuticals,加入 Clariti 鏡片及日拋鏡片產能。
2021CooperSurgical 於2021年12月以16億美元收購 Generate Life Sciences,建立領先的生育服務平台;原定以8.75億美元收購 Cook Medical 生殖健康業務的交易於2022年2月公布,惟於2023年8月經聯邦貿易委員會審查後終止,從未交割。

競爭地位

  • Johnson & Johnson Vision(Acuvue)— 全球最大的隱形眼鏡對手。
  • Alcon — 全球前二的隱形眼鏡製造商,是 CooperVision 規模最接近的競爭對手。
  • Bausch + Lomb — 在隱形眼鏡及眼部健康產品方面競爭。
  • 生育及女性健康方面:Vitrolife、Cook Medical(餘下產品線)及其他專科器械製造商。

財務快照

總收入40.92 億美元(2025 財年收入)
營業利潤6.83 億美元(2025 財年營業利潤)
淨利潤3.75 億美元(2025 財年淨利潤)
稀釋 EPS1.87 美元(2025 財年稀釋 EPS)
資料來源:The Cooper Companies, Inc. 2025 財年 Form 10-K(截至2025年10月31日止年度;2025年12月5日提交)。確實數字:總收入40.92億美元(4,092.4百萬美元);經營溢利6.83億美元(682.9百萬美元);淨溢利3.75億美元(374.9百萬美元);攤薄每股盈利1.87美元。截至2025年10月31日,公司員工總數逾15,000人(美洲佔52%、歐洲、中東及非洲佔42%、亞太區佔6%)。截至2026年11月5日,2026財年業績尚未以 Form 10-K 提交。

主要風險

  • 管理層交接:總裁兼行政總裁 Albert G. White III 於2026年10月27日卸任,現由臨時執行主席主持,常任行政總裁遴選進行中。
  • 來自 Alcon、Johnson & Johnson Vision 及 Bausch + Lomb 的隱形眼鏡競爭及價格壓力,以及自家品牌和直銷品牌的挑戰。
  • 以債務融資收購生育業務(Generate Life Sciences)後的 CooperSurgical 利潤率及整合風險。
  • 鏡片及醫療器械在美國食品藥物管理局及國際市場的監管與產品質素風險,以及全球銷售與生產布局帶來的匯率風險。

對標普500的重要性

Cooper Companies 是健康護理股中權重較小的成份股:截至2026年11月5日,按權重排名第473位,權重0.02%,在健康護理板塊60隻股票中排第54位。它是指數內對全球隱形眼鏡市場最大規模的純粹敞口,並配以透過收購建立的生育及女性健康器械業務。

來源與方法

財務、板塊、總部The Cooper Companies, Inc. 2025 財年 Form 10-K,經 SEC EDGAR 取得(見財務摘要附註);總部、行政總裁及歷史資料來自 Form 10-K 及維基百科公司條目
指數權重與排名Slickcharts 標普 500 權重,Nov 5, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS)
市值$12.31B(Slickcharts,Nov 5, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

COO

來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · COO
Data as of Nov 5, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · The Clorox Company (CLX) — XLP Consumer Staples · S&P 500 Profile |高樂氏公司介紹Next · Globe Life Inc. (GL) — XLF Financials · S&P 500 Profile |Globe Life公司介紹

Entered 2026-11-04 14:30 · updated 2026-11-14 23:11 · rev 9